Lupus
2 years ago
Combined estrogen-progestin contraception in SLE patients with positive aPL conferred an increased risk of thrombosis relative to progestin-only contraception. Abs 0943 #ACR22 @RheumNow https://t.co/B2Wmhlz6at https://t.co/YlvqoYY8FN
2 years ago
Ab1117 #ACR22 Deucravacitinib: TYK2 inhibitor in active SLE?
363 pt P2, double-blind PBO-controlled 48 wk study
DEUC 3 mg BID, 6 BID, 12 QB vs PBO:
At 32wk: DEUC 3BID & 6BID > PBO, sustained across all groups at 48wk.
AEs: similar bw PBO and DEUC. No VTE
@RheumNow #ACRBest https://t.co/uamJe05odq
2 years ago
Interstitial inflammation in the entire cortical parenchyma in areas w/ and w/o fibrosis identifies at risk SLE pts for CKD progression. Abs 0634 #ACR22 @RheumNow https://t.co/3iBYHPyYXL https://t.co/iSwblT2Amm
2 years ago
Most rheums round down on dosing because of the weight based recc's, but hydroxychloroquine dosing less than 5 Mg/kg/day leads to increased hospitalizations for #SLE flares abst#1654 #ACR22 #PressConference @rheumnow https://t.co/GGnnl14cy9
2 years ago
Stop repeating the #ANA test!
46% of all ANA tests were repeat tests in this study. #HealthCareCost #NoUtility #ChooseWisely abst#1278 @rheumnow #ACR22 https://t.co/K7oyqJYvi9
2 years ago
Favorable kidney outcomes observed for BEL vs PBO in pts with SLE, including fewer kidney flares, greater kidney improvement (SELENA-SLEDAI), less kidney worsening (BILAG), and improved eGFR. Abs 0352 #ACR22 @RheumNow https://t.co/w50uEYVDup https://t.co/JyKZEZG6DZ
2 years ago
I questioned HCQ dose reducing in my recent newsletter & podcast; more evidence!
Receiving less HCQ = more damage and more CVD
Observational, not clearly causal, but should make you wonder...
Are we sure we should be shooting for <5mg/kg/day?
#ACR22 @RheumNow #0982 https://t.co/SuAwSumgu1
2 years ago
Updates on Reproductive Health in Women with SLE
https://t.co/E09cvQbVoD
#ACR22 https://t.co/Ausa6ELoHe
2 years ago
In non-renal SLE, BEL associated w/ a lower risk of severe infection and hospitalizations due to severe infection compared to MTX, AZA, MMF. Abs 0349 #ACR22 @RheumNow https://t.co/0EBpCMPOqF https://t.co/vdxKVJSaZA
2 years ago
Isenberg et al. Atacicept 150mg in SLE. Reduced flare 36% vs 53%, delayed time to first flare, stabalised renal function (vs decline in PBO), less steroid increase (14% vs 36%), UPCR declined (vs increase in PBO) @RheumNow #ACR22 Abstr#1001 https://t.co/FRWcTAgCrn https://t.co/Amkg84OX2x